COPENHAGEN, Denmark, July 31, 2025 - Bavarian Nordic A/S (OMX: BAVA) today announced the completion of the sale of its ...

The directors of the vaccine maker said the offer from Permira and Nordic Capital was an attractive proposal and recommended that shareholders accept it.

Amid a new strain of mpox, the Danish company is preparing to make millions of vaccine doses to supply to the world.

That’s how many vaccine doses Bavarian Nordic says it can supply by the end of 2025. Two million of these will be available over the remainder of 2024, the company said, a figure that includes ...

Danish biotechnology company Bavarian Nordic, the only producer of a vaccine approved against monkeypox, has been approached by many countries keen on procuring vaccines against the disease which ...

Employees of a Bavarian Nordic factory near Munich, Germany, are under pressure to produce more monkeypox vaccine doses as cases across the globe break 40,000, including a handful of deaths.

Vaccine maker Bavarian Nordic on Monday said it has agreed in principle to a roughly $3 billion take-private offer from private equity firms Nordic Capital and Permira.

Shares in Bavarian Nordic - one of the few drug firms with an mpox vaccine - were up about 19% since market close on Aug. 13, the day before the WHO announcement.

Bavarian Nordic is also working on a tumor antibody-boosted therapeutic vaccine called TAEK-VAC, which is being investigated in an open-label phase 1/2 study in patients with breast and lung cancer.

Danish biotech firm Bavarian Nordic said on Tuesday it will donate 40,000 doses of its mpox vaccine to Africa's top public health body, after the body declared an emergency.

Now, Bavarian Nordic has shared a glimpse at how the vaccine may fare against omicron, the variant that has swept the world since the company began the phase 2 trial. Omicron neutralizing antibody ...

BAVARIAN NORDIC (BVNRY) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates ...